Key result
Galectin-9 inhibits enterovirus replication and pathogenicity by directly interacting with the viral VP2 protein.
Why the study?
Galectin-9 is implicated in various viral infections, but its role in enterovirus infections remains unexplored.
Does Galectin-9 restrict enterovirus infection in preclinical models?
Does Galectin-9 restrict enterovirus infection in preclinical models?
Galectin-9 acts as a host restriction factor against enteroviruses by directly interacting with the viral VP2 protein, suggesting a potential target for antiviral strategies.
Hypothesis-generating for Galectin-9 antivirals in enterovirus infection; extends animal data but leaves open clinical translation.
Enteroviruses (EVs), encompassing over 200 sero/genotypes, cause diseases ranging from mild illness to severe systemic infections. Galectin-9 (Gal-9) is an immunomodulatory lectin implicated in various viral infections, yet its role in EVs remains unexplored. Here, we identify Gal-9 as a novel host restriction factor against a broad spectrum of EVs, including EV-A71, EV-D68, and Coxsackievirus B2. LGALS9 deficiency increased viral replication in cells and pathogenicity in a mouse model of EV-A71 infection, while its overexpression inhibited viral replication. Mechanistically, Gal-9 specifically interacts with the viral VP2 protein, and mapping identified residues 179–194 of Gal-9 as critical for this interaction. A Gal-9 Δ179–194 mutant lost VP2-binding capacity and antiviral activity. These findings reveal that Gal-9 is a key component of the host antiviral response against EVs, functioning through a direct interaction with the viral VP2 protein. IMPORTANCE Enteroviruses (EVs) cause a wide spectrum of disease and present a persistent global health challenge, highlighted by the cyclical resurgence of strains like EV-D68 and EV-A71. However, due to a lack of sufficient understanding of their pathogenesis, no EV-specific antiviral drugs are available. This study demonstrates that galectin-9 (Gal-9) is a key host factor that broadly antagonizes EVs, including EV-A71, EV-D68, and Coxsackievirus B2. We show that Gal-9 deficiency enhances viral replication both in cell culture and in an animal model. By identifying Gal-9 as a crucial restriction factor against EVs, our study provides foundational insight for the future development of antiviral strategies.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2026) studied this question. Galectin-9 acts as a broad host restriction factor against multiple enteroviruses by directly interacting with the viral VP2 protein to inhibit viral replication and pathogenicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: